Blog Detail

BioMedReports.com

http://biomedreports.com/blog.html

BioMedReports.com is a website for healthcare investors and traders, which features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content – including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into new healthcare stock indexes.

The Managing Editor, Mike Havrilla, is an index developer and writer with experience that includes online investing since August 1997 and freelance writing for investors since April 2007 with a focus on the healthcare sector. Mike holds Doctor of Pharmacy (2003) and Bachelor of Science (Biology) (1998) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner since 1992 and has completed 18 marathons with a personal best time of 2 hours, 54 minutes for the 26.2 mile race.

• Added on: Mar 11th, 2009
• Country: United States
• Language: English

• Author: Mike Havrilla
• Listed in: Business Medicine
• Tags: medical biotech fda pharmaceutical clinical trial health indexes

Recent Posts

• BioMed News Bytes: Antigenics, King, Shire, Delcath

  Posted on Wednesday October 21st, 2009 at 08:51

  On 6/1/09, Antigenics (NASDAQ: AGEN) announced results of an interim analysis from the Company’s ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an appr...

• BioMed News Bytes: Angiotech, BioSante, HGSI

  Posted on Tuesday October 20th, 2009 at 08:09

  On 10/19/09, Angiotech Pharma (NASDAQ: ANPI) received notice from the FDA that Bio-Seal is a Class III medical device that requires Pre-Market Approval (PMA) for marketing clearance by the Agency. As a result, ANPI is reviewing its options with respe...

• Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

  Posted on Monday October 19th, 2009 at 19:27

  At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the ...

• NF Energy (OTC: NFEC.OB): An Efficient China Growth Play

  Posted on Saturday October 17th, 2009 at 18:22

  NF Energy Saving Corp. (OTC: NFEC.OB) provides emission reduction and energy saving equipment / services for China’s rapidly growing cogeneration sector. The Company also manufactures wind power equipment and flow control systems for coal, hydro, a...

• FDA Approves Glaxo’s (NYSE: GSK) Cervical Cancer Vaccine

  Posted on Friday October 16th, 2009 at 09:59

  On 10/16/09, GlaxoSmithKline (NYSE: GSK) announced that the FDA approved CERVARIX [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human pa...

• BioMed News Bytes: Cytori (NASDAQ: CYTX), Questcor (NASDAQ: QCOR)

  Posted on Thursday October 15th, 2009 at 20:14

  Cytori Therapeutics (NASDAQ: CYTX) sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) that d...

Comments & Reviews

There is no rating for this blog because there are no comments yet.

Post A Comment/Review

* Your IP is being logged.
* Your e-mail address is used only for verification purposes only and will not be sold, or shown publicly.
* No HTML tags allowed
* DO NOT use the Comments/Reviews to promote your own site.